Affinivax reacquires rights from Astellas for ASP3772

1 March 2022

US biotech Affinivax yesterday announced it has reacquired the exclusive worldwide rights to ASP3772, a novel vaccine candidate targeting Streptococcus pneumoniae, from Japanese pharma major Astellas Pharma (TYO: 4503).

In conjunction with the rights reacquisition by Affinivax, ASP3772 will be renamed AFX3772. Closing of the transaction is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act, which is expected in March or April of 2022.

Under the terms of the new agreement, Astellas will receive a $65 million upfront payment and will be eligible for milestone payments and royalties tied to the clinical development and commercialization of ASP3772, as well as royalties tied to the commercialization of Affinivax’ next generation pneumococcal vaccine products designed to treat Streptococcus pneuomoniae.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK